Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids.
about
Pentoxifylline for alcoholic hepatitisCurrent Management of Alcoholic Hepatitis and Future TherapiesNew treatment options for alcoholic hepatitisManaging alcoholic liver diseaseDiagnosis and Management of Alcoholic Liver DiseaseAlcoholic liver disease: pathogenesis, management, and novel targets for therapyAlcoholic hepatitis: a comprehensive review of pathogenesis and treatmentAlcoholic liver disease: pathogenesis and new therapeutic targets.Pilot study of pentoxifylline in hepatopulmonary syndrome.Alcoholic liver disease: treatmentAlcoholic hepatitis: current challenges and future directions.Severe alcoholic hepatitis-current concepts, diagnosis and treatment options.Treatment of alcoholic liver disease.Treatment of decompensated alcoholic liver disease.Cilostazol Decreases Ethanol-Mediated TNFalpha Expression in RAW264.7 Murine Macrophage and in Liver from Binge Drinking MiceDiagnosis and Treatment of Alcoholic Hepatitis: A Systematic Review.Pentoxifylline in hepatopulmonary syndromeAlcoholic Hepatitis: Steroids vs. PentoxifyllineSteroids or pentoxifylline for alcoholic hepatitis (STOPAH): study protocol for a randomised controlled trial.KASL clinical practice guidelines: management of alcoholic liver diseaseTrends in the management and burden of alcoholic liver disease.Case of severe alcoholic hepatitis treated with granulocytapheresis.Practical Concerns and Controversies in the Management of Alcoholic Hepatitis.The management of alcoholic hepatitis.Diagnosis and management of alcoholic liver disease.Alcoholic hepatitis: diagnosis and management in 2012.Systematic review: pentoxifylline for the treatment of severe alcoholic hepatitis.Prognosis and treatment of patients with acute alcoholic hepatitis.Alcoholic hepatitis: current management.Corticosteroids and pentoxifylline for the treatment of alcoholic hepatitis: Current status.Clinical and microbiological features of infection in alcoholic hepatitis: an international cohort study.New paradigms in management of alcoholic hepatitis: a review.Review article: recent insights into clinical decision-making in severe alcoholic hepatitis.Pentoxifylline: a first line treatment option for severe alcoholic hepatitis and hepatorenal syndrome?Expression of bax and bcl2 Genes in MDMA-induced Hepatotoxicity on Rat Liver Using Quantitative Real-Time PCR Method through Triggering Programmed Cell Death.Pentoxifylline Protects the Rat Liver Against Fibrosis and Apoptosis Induced by Acute Administration of 3,4-Methylenedioxymethamphetamine (MDMA or Ecstasy).Theophylline improves steroid sensitivity in acute alcoholic hepatitis.The management of alcoholic hepatitis: a prospective comparison of scoring systems.[Management of severe alcoholic hepatitis].Alcohol abstinence in patients surviving an episode of alcoholic hepatitis: Prediction and impact on long-term survival.
P2860
Q24240223-1F9DA007-6B9B-429B-930F-79CB3F0648FDQ26746544-1138DA23-22E5-4713-B675-8AA8238712E8Q26751402-E8F3032C-B5AC-44D4-8B8D-DBBBD81F7AAEQ26777480-45C141D8-AC9B-4134-B0E1-CCCF81915D1DQ26781876-F0424716-5A49-4436-A87C-7F619F9EBA61Q26861620-09F7629B-138A-4BBD-AE60-084240AB0A35Q27027418-7191E2BF-2463-4C8A-8698-73DF4374FA28Q27690220-A050A794-9B6E-42A3-B680-CE23F909ED5AQ33712172-56A05C6D-C979-463D-9733-1DCF901982E1Q34255479-D8601B70-E18F-4799-B27E-2C8FD131BEECQ34354286-0B06624F-FA46-40C4-94DC-B019BABBB544Q34404386-14D34FBB-BAE5-4E48-B047-2B13F7B4FA4AQ34565692-EABBB7B1-C95A-4581-9EE9-620A77618E38Q35207505-042E6666-6ADC-4F2E-9929-46381A649387Q35919812-275B95A6-130A-48B1-85D9-9DA569B06D48Q36038296-9FE0030F-C9EE-4E8B-9285-E7A94D791C93Q36248200-AEBC96AF-3F0E-46D5-8EC2-C0F526482F9DQ36899751-3D7A4E13-BE93-4C3B-8465-A71A64F31A6FQ37153909-AC5620F0-1C35-484E-958D-1992196F3C2DQ37229858-B827A5D4-532B-4071-9501-6837F8111B7EQ37237035-F8DAE651-A7A1-4F22-A3DC-0BA457D967C0Q37418907-B74E3B91-67C3-415B-B2C4-46BBFF67F142Q37421502-F3DC43E1-452C-4540-8B35-D6AADE1287FEQ37676833-65F801A5-77E2-4C99-A6D0-2A055DED1BD2Q37811070-9B750470-3868-47E0-817E-061ECA254C55Q38067131-EB3D0771-F383-4748-84BA-CE27B36BE27DQ38089162-7B346FFE-723E-4228-A8F0-74FF3D06A1CEQ38203313-5B0F4C55-DED5-4171-94A6-F3D15C8D2E17Q38209601-EEF353C0-F504-48E5-80F8-A73F733B374BQ38567064-9F0E38D3-1819-4342-A423-C90CCC1D5485Q38847072-B76C18DB-30F5-485B-B20C-69B9846220AEQ39155727-8B6DE737-640A-4C82-8EBE-1AAE8317E4C3Q39329505-11A0971F-8307-4445-AB1F-20D753AD0E64Q39965729-F1137AB8-D142-4947-BAFE-0B07DAE33412Q40144017-161D331D-0C9A-4011-BB3F-D958202FA18AQ41933115-FC7EFE11-2870-47CC-8DA0-B96DD1EF451AQ43005649-69E39BC5-B8D6-4325-8834-F7B9BC09E908Q44131679-9AE8464C-6FB1-4DDF-AAD9-6AF9BDB66A9AQ44181725-6280DC13-5846-4FC3-8977-9AF65950A0E1Q47789708-60C97086-F9FE-49E2-901C-E97F973BD558
P2860
Early switch to pentoxifylline in patients with severe alcoholic hepatitis is inefficient in non-responders to corticosteroids.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Early switch to pentoxifylline ...... responders to corticosteroids.
@en
Early switch to pentoxifylline ...... responders to corticosteroids.
@nl
type
label
Early switch to pentoxifylline ...... responders to corticosteroids.
@en
Early switch to pentoxifylline ...... responders to corticosteroids.
@nl
prefLabel
Early switch to pentoxifylline ...... responders to corticosteroids.
@en
Early switch to pentoxifylline ...... responders to corticosteroids.
@nl
P2093
P1476
Early switch to pentoxifylline ...... -responders to corticosteroids
@en
P2093
Christophe Plane
Emmanuel Diaz
Frédéric Texier
Hugues Coevoet
Pierre Deltenre
Sébastien Dharancy
Thierry Thévenot
Valérie Canva
P304
P356
10.1016/J.JHEP.2007.10.010
P577
2007-11-26T00:00:00Z